No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:23:37.780Z. Latest historical point 2026-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Tvardi Therapeutics, Inc. (TVRD) stock was $1.08 as of Oct 6, 2026, 4:00 PM EDT, down 5.26% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -97.1%
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Biotechnology · Sugar Land, TX
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.55
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.69
vs Estimate
$-0.70
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TVRD | $10.13M | $1.08 | -5.26% | -97.12% | N/A | N/A | N/A |
| 2SNTI | $10.06M | $0.32 | -6.40% | -78.27% | -67.75% | N/A | vs TVRD |
| 3MDCX | $10.06M | $0.16 | -4.67% | -93.34% | N/A | N/A | vs TVRD |
| 4LFWD | $10.21M | $6.34 | -4.95% | -28.40% | -43.18% | -53.24% | vs TVRD |
| 5VBIO | $9.86M | $2.38 | -4.03% | -96.66% | N/A | N/A | vs TVRD |
| 6NMTC | $9.83M | $1.13 | +1.35% | -79.77% | -46.02% | N/A | vs TVRD |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$9.25
+756.5% upside
Low
$3.00
Current
$1.08
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.79 | $-0.55 | $-0.30 | 6 |
| Quarter ending Dec 2026 | $-0.63 | $-0.41 | $-0.22 | 6 |
| Quarter ending Mar 2027 | $-0.36 | $-0.36 | $-0.36 | 2 |
| Quarter ending Jun 2027 | $-0.36 | $-0.36 | $-0.36 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.89 | $-2.25 | $-1.53 | 6 |
| FY 2027 | $-3.35 | $-2.06 | $-0.62 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
